Cannabis is still a Schedule I controlled substance under federal law. The DEA has proposed moving it to Schedule III, but no final rule has taken effect, so federal penalties, research limits, and tax rules stay in place until a final rule is published and its effective date arrives. That is the short version of the cannabis rescheduling update.

How the process reached this point

Rescheduling is a rulemaking, not a vote in Congress. It moves through agency review, public comment, and formal hearings before anything is final.

  • October 2022: the White House asked the Department of Health and Human Services and the Justice Department to review how cannabis is scheduled.
  • August 2023: HHS recommended Schedule III after a scientific review led by the FDA.
  • May 2024: the DEA published a notice of proposed rulemaking to move cannabis from Schedule I to Schedule III.
  • Since then: a DEA administrative law judge has taken testimony from supporters and opponents of the change.
  • Still ahead: a recommended decision, a final rule in the Federal Register, and an effective date.

Because each step can be challenged in court, timelines stay uncertain. Anyone claiming a firm date is guessing.

Schedule I versus Schedule III

Schedule I means the federal government recognizes no accepted medical use and applies the tightest controls. Schedule III means accepted medical use with lower abuse potential and prescription access through DEA-registered handlers.

The practical difference for licensed businesses is tax treatment. Section 280E blocks deductions and credits for businesses trafficking in Schedule I or II substances. Moving to Schedule III would remove that barrier, which is why operators watch this file so closely.

What rescheduling would not do

  • It would not legalize cannabis for adult use.
  • It would not create a national medical cannabis program.
  • It would not override state laws, including states where cannabis remains prohibited.
  • It would not put cannabis on pharmacy shelves like an ordinary prescription drug.
  • It would not change rules for hemp.

Where hemp-derived CBD fits

Hemp containing no more than 0.3 percent THC on a dry weight basis was removed from the Controlled Substances Act by the 2018 Farm Bill. Hemp-derived CBD therefore sits outside the rescheduling debate, and its legal status does not hinge on the DEA's decision. State rules still vary, and quality still varies far more. Look for a batch-specific certificate of analysis from an independent lab before you buy.

What to watch next

  • The administrative law judge's recommended decision.
  • The final rule and its stated effective date in the Federal Register.
  • Any court appeals filed after the rule is issued.
  • State licensing and tax responses.

Until a final rule lands, treat cannabis as federally prohibited and rely on state law where you live. This is general information, not legal advice.